Influenza Hemagglutinin (HA) Peptide: High-Purity Epitope Tag for Protein Purification and Detection

Executive Summary: The Influenza Hemagglutinin (HA) Peptide (sequence: YPYDVPDYA) is a synthetic, nine–amino acid epitope tag derived from the human influenza virus hemagglutinin protein. It is widely utilized in molecular biology for its capacity to facilitate the detection, purification, and elution of HA-tagged fusion proteins via competitive binding to anti-HA antibodies (APExBIO). The peptide displays high solubility in DMSO (≥55.1 mg/mL), ethanol (≥100.4 mg/mL), and water (≥46.2 mg/mL), enabling compatibility with diverse buffer systems. High chemical purity (>98%) is confirmed by HPLC and mass spectrometry, ensuring reliable experimental outcomes (Dong et al., 2025). Its use is pivotal in high-specificity immunoprecipitation and protein–protein interaction studies, including advanced research on ubiquitination and cancer signaling.

Biological Rationale

The HA tag peptide is derived from the influenza virus hemagglutinin protein’s epitope, specifically the sequence YPYDVPDYA. This region is recognized with high affinity by monoclonal anti-HA antibodies, making it a preferred choice for tagging recombinant proteins (APExBIO). The tag’s small size (9 amino acids) minimizes structural perturbation of the fusion protein. The HA tag is widely adopted for its reliability in protein expression analysis, immunoprecipitation, and Western blotting workflows (HA Peptide for Precision Tagging). This article provides an updated, benchmark-driven perspective compared to existing guides by emphasizing quantitative solubility, purity, and validated use in advanced ubiquitination research.

Mechanism of Action of Influenza Hemagglutinin (HA) Peptide

The HA peptide functions as a competitive ligand for anti-HA antibodies. When added to immunoprecipitation or affinity purification assays, the free HA peptide binds to the paratope of the antibody, displacing HA-tagged proteins from the antibody complex (Advanced Use-Cases Guide). This competitive elution mechanism enables the selective release of HA-tagged proteins under mild, non-denaturing conditions, preserving protein structure and activity. The molecular interaction is highly specific due to the sequence fidelity of the HA tag, which matches the antibody’s epitope recognition region. This property supports quantitative recovery of target proteins during immunoprecipitation, as demonstrated in cancer signaling studies requiring the isolation of transient protein complexes (Dong et al., 2025).

Evidence & Benchmarks

• High chemical purity (>98%) of the HA peptide is confirmed by HPLC and mass spectrometry, ensuring minimal contaminants in molecular workflows (APExBIO).
• The HA tag sequence (YPYDVPDYA) is universally recognized by monoclonal anti-HA antibodies (clone 12CA5 and others), supporting cross-laboratory reproducibility (Benchmark Epitope Tag Article).
• Solubility benchmarks: ≥55.1 mg/mL in DMSO, ≥100.4 mg/mL in ethanol, and ≥46.2 mg/mL in water at 25°C, pH 7.4, supporting preparation of high-concentration working stocks (APExBIO).
• Competitive elution with HA peptide enables recovery of HA-tagged proteins from anti-HA antibody beads within 30 minutes under non-denaturing conditions (Dong et al., 2025, DOI).
• Validated use in ubiquitination research, including protein–protein interaction studies and signal transduction assays, such as AKT/mTOR pathway analysis (Dong et al., 2025).

Applications, Limits & Misconceptions

The Influenza Hemagglutinin (HA) Peptide is used as a molecular tag for:

• Detection of HA-tagged proteins by Western blot, ELISA, and immunofluorescence.
• Purification of HA-tagged fusion proteins via immunoprecipitation with anti-HA magnetic beads or antibodies.
• Competitive elution of HA-tagged proteins during immunoprecipitation (“soft elution”).
• Protein–protein interaction studies, including mapping of ubiquitination targets in cancer research (Dong et al., 2025).

This article extends the protocol-centric approach of Applied Workflows with Influenza Hemagglutinin (HA) Peptide by focusing on evidence-based solubility data and cross-validated use in ubiquitination and advanced cancer signaling models.

Common Pitfalls or Misconceptions

• The HA peptide is not suitable for eluting proteins tagged with unrelated epitope tags (e.g., FLAG, Myc).
• Excess peptide may not improve elution efficiency and can interfere with downstream antibody-based assays.
• Long-term storage of peptide solutions (>1 week at 4°C or –20°C) is not recommended due to potential degradation; always store lyophilized at –20°C.
• The HA tag does not confer affinity for non-HA antibodies or general protein purification resins.
• Overuse can saturate antibody binding sites, reducing specificity in multiplexed assays.

Workflow Integration & Parameters

The HA peptide is typically reconstituted at 1–5 mg/mL in water, DMSO, or ethanol, based on downstream buffer compatibility. For immunoprecipitation, 0.5–2 mg of HA peptide is added per 1 mL of antibody-conjugated bead suspension. Elution occurs at 4–25°C, pH 7.0–8.0, with gentle agitation for 15–30 minutes. The peptide is compatible with common lysis buffers (e.g., RIPA, NP-40) provided the final organic solvent concentration does not exceed 5% (v/v). Purified proteins are suitable for downstream SDS-PAGE, Western blot, and mass spectrometry (Stepwise Workflow Article). This section clarifies updated solubility and stability parameters beyond previous stepwise guides.

Conclusion & Outlook

The Influenza Hemagglutinin (HA) Peptide (A6004, APExBIO) sets a reproducibility benchmark for epitope tag peptides in molecular biology. Its high purity, robust solubility, and validated performance across immunoprecipitation, protein–protein interaction, and ubiquitination studies make it a standard in research workflows. Future advances may involve multiplexed tagging strategies and further automation of immunoprecipitation protocols, but the HA tag remains foundational for protein detection and purification due to its specificity and practical reliability (Dong et al., 2025).